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AbsTrACT
background/Aim To report the efficacy and tolerability 
of antitumour necrosis factor-alpha therapy (TNF 
inhibitors [TNFi]) in the management of non-infectious 
ocular inflammation, including uveitis and scleritis, in 
adult patients over an 8-year period.
Materials and methods This is a prospective cohort 
study of infliximab and adalimumab in the treatment 
of non-infectious ocular inflammatory disease. 43 of 85 
adult patients on TNFi (34 infliximab, 9 adalimumab) 
for ≥1 year with non-infectious uveitis or scleritis were 
followed from 2006 to 2014. Clinical assessments, 
medication, adverse events and history of steroid rescues 
were collected at 6 monthly intervals. General quality 
of life (Short Form Health Survey (SF-36)) and visual 
quality of life (Vision-related quality of life Core Measure 
(VCM1)) were assessed annually. Outcome measures 
included rate of sustained remission, rate of relapse, 
systemic corticosteroid reduction, adverse events, and 
VCM1 and SF-36 scores.
results The median time on infliximab was 3.2 years 
(IQR 4.3) and on adalimumab was 2.4 years (IQR 1.8). 
Sustained remission was induced in 39 patients (91%) 
(0.5 per patient year) after a median of 1.2 years 
on a TNFi. 22 (51%) experienced one relapse, and 5 
(12%) had two relapses. 23 (54%) had at least one 
adverse event; serious adverse events necessitating 
hospitalisation or cessation of medication occurred in 
four (9%) patients. 10 patients (23%) switched from the 
initiation of TNFi, at 1.7 years after starting, to another 
TNFi or another class of biologic therapy.
Conclusion TNFi treatment is associated with long-
term drug-induced remission of ocular inflammation, 
visual stability and corticosteroid reduction. Adverse 
events were common and no new safety signals 
occurred. Relapse of inflammation occurs in half of the 
treated population.
InTroduCTIon
Sight-threatening non-infectious uveitis is respon-
sible for up to 10%–15% of blindness in the devel-
oped world.1 2 The biologic agents, tumour necrosis 
factor-alpha (TNFα) inhibitors (TNFi)1 2 and inter-
feron-α,3 4 are treatment alternatives to conven-
tional immunosuppressants for uveitis and as early 
therapies in Behcet’s disease or for refractory 
uveitis.1 2 5 Infliximab is effective in inducing and 
maintaining remission in up to 86% of patients 
with uveitis and particularly in Behcet’s disease.5 6 
The VISUAL I and II trials evidence the ability of 
adalimumab to reduce the number of uveitis flares 
compared with placebo (28% and 20% for VISUAL 
I and II, respectively) and enable corticosteroid 
reduction over an 80-week period.1 2 An open-label 
extension of the original VISUAL trials for active 
and inactive uveitis provides further evidence of 
efficacy7 and patient-reported measures inform 
visual functioning ability.8 In a post-hoc analysis of 
participants with active and inactive uveitis treated 
with adalimumab within the VISUAL trials, there 
was an improvement in at least 75% of the VQF25 
visual quality of life (QoL) questionnaire subcom-
ponents compared with placebo.9 Non-infectious 
scleritis is a typically painful inflammatory disorder 
which has also been treated with TNFi.10
TNFi has been used regularly in clinical prac-
tice in ocular inflammation for over a decade. This 
prospective immunosurveillance study aimed to 
capture clinical indices for patients on TNFi, to 
obtain insight into long-term patient response char-
acteristics for the two most widely available TNFi 
therapies for ocular inflammation.
PATIenTs And MeThods
data collection
Longitudinal, cohort data for patients receiving 
TNFi were captured within an electronic data-
base hosted on a National Health Service digital 
network. This analysis reports an 8-year outcome 
data and QoL parameters for patients over the age 
of 18 years old treated with TNFi for at least 1 year 
from October 2006 to May 2015 at Bristol Eye 
Hospital, UK (figure 1).
For six patients who started TNFi before the 
study, baseline visit data were collected retrospec-
tively from patients’ notes (table 1). We prospec-
tively recorded clinical activity parameters, adverse 
events (AEs) and medications at 6 monthly dedi-
cated clinics. QoL was assessed annually. Clinical 
assessment included a full systemic history, loga-
rithm of the minimum angle of resolution (logMAR) 
visual acuity with current spectacle correction, 
Goldmann tonometry, slit-lamp examination, and 
fundal examination including biomicroscopic indi-
rect ophthalmoscopy (BIO) to score vitreous haze. 
Intraocular inflammation was graded according to 
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Figure 1 Study Diagram.
Standardised Uveitis Nomenclature.11 The presence or absence 
of vasculitis and macular oedema was scored by clinical exam-
ination and ocular imaging. Scleritis was scored clinically as 
active or inactive.
Immunosuppressant medication, corticosteroid doses and 
corticosteroid ‘rescue’ treatments were recorded. Treatment 
decisions for immunomodulatory agents followed a paradigm 
contemporary for uveitis practice prior to current trial data. 
Patients on biologic therapy were maintained on a single immu-
nomodulatory therapy in order to diminish the formation of 
human antichimeric antibodies. Typical immunomodulatory 
agents and doses were infliximab 3–5 mg/kg 4–8 weekly via 
intravenous administration, adalimumab 40 mg alternate weeks 
via subcutaneous route, mycophenolate mofetil 1–3 g/day and 
tacrolimus titrated to whole blood trough levels of 5−10 ng/L. 
If there was a failure to respond to TNFi, we adopted a strategy 
to optimise background immunosuppression to tolerated ther-
apeutic levels, followed by in-class switching and lastly, out-of-
class switching. Treatment cessation was immediate where serious 
adverse events (SAEs) occurred. Steroid rescue treatment was 
defined as a short escalation of corticosteroids given either intra-
venously as methylprednisolone (500 mg–1 g/day for 3 days), 
a tapering course of high-dose oral prednisolone (starting ≥40 
mg, tapering to ≤7.5 mg/day), periorbital corticosteroid injec-
tion (triamcinolone 40 mg), intravitreal triamcinolone injection 
(4 mg) or a dexamethasone (Ozurdex) intravitreal implant. Data 
on steroid rescue events prior to biologic therapy were collected 
retrospectively from patients’ clinical records.
Patients
Patients with non-infectious uveitis and scleritis receiving TNFi 
for 1 year, who were over the age of 18 years, had a negative or 
treated tuberculosis (TB) status, had been on no other biologic 
therapy, and had at least two recorded attendances in the biologics 
registry clinic were eligible for inclusion (figure 1). Informed 
consent was obtained from patients prior to participation.
data analysis and statistics
The principal outcome measure was the rate of achieving 
sustained remission defined as anterior chamber inflammation 
and vitreous haze scores of ≤0.5+ on two successive visits, 
absence of retinal vasculitis or worsening cystoid macular 
oedema. The event rate is defined as the total number of events 
as a proportion of the time from TNFi initiation to the event to 
census, reported as incidence rates per patient year (PPY).
The secondary objectives included the following:
 ► Relapse rate (requirement for steroid rescue therapy, two-step 
increase in anterior chamber (AC) activity or vitreous haze 
score, new cystoid macular oedema, retinal vasculitis on 
fluorescein angiography, or a doubling of the visual angle).
 ► Reduction of daily oral prednisolone to ≤10 mg for two 
successive visits.
 ► Doubling or halving of the visual angle (loss or gain of 15 
letters on the ETDRS chart) compared with baseline on two 
successive visits.
 ► Rate of AEs.
 ► Vision-related quality of life Core Measure (VCM1) and 
Short Form Health Survey -36 (SF-36) QoL scores.
Relapse and remission rates during TNFi treatment are 
presented as cumulative incidence curves using the product limit 
method of Kaplan and Meier and calculated using the statistical 
package ‘survival’ in ‘R’ (where patients who did not experience 
the endpoint before the end of their follow-up were censored).
QoL scores were compared annually using the UK standard 
version of the SF-36.12 Vision-related QoL was measured using 
VCM1, which is validated for uveitis.13 14 To account for with-
in-hospital clustering, generalised estimating equations were 
used to generate models using sex, BIO score, duration of treat-
ment and visual acuity as potential predictive variables. For 
VCM1 a binomial distribution was used to determine which 
variables were predictive of a VCM1 score of more than 2.0 
(which reflected a patient experiencing ‘more than a little’ 
concern about their vision).13
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Table 1 Patient demographics and disease characteristics at 
baseline (prior to commencement of TNFi)
demographics %
Cohort size 43 –
Age at study entry (SD) 38.9 (11.6) –
Female gender 27 62.8
Ethnicity
  Caucasian 42 97.7
  Asian 1 2.3
  Afro-Caribbean 1 2.3
Bilateral disease 31 72.3
Median duration of disease prior to biologic therapy, years (IQR) 3.0 (7.0)
Anatomical classification of ocular disease
  Anterior uveitis 3 7
  Intermediate uveitis 8 18.6
  Panuveitis 13 30.2
  Posterior uveitis 15 34.9
  Scleritis 4 9.3
Aetiology
  Idiopathic 19 44.2
  Systemic vasculitis 1 2.3
  Ankylosing spondylitis 1 2.3
  Behcet’s 15 34.8
  Juvenile idiopathic arthritis 2 4.6
  Juvenile sarcoidosis 1 2.3
  Psoriatic arthropathy 2 4.6
  Sarcoidosis 1 2.3
  Undifferentiated arthritis 1 2.3
Visual acuity logMAR score
  ≤0 14 33
  >0.1, ≤0.3 18 41.8
  >0.3, ≤1 9 20.9
  >1 2 4.6
Clinical disease activity
  Anterior chamber inflammation ≥1+ 7 16.3
  Cystoid macular oedema (active inflammation) 9* 20.9
  Vitreous haze score ≥1 5 11.6
  Retinal vasculitis 23 53.5
  Choroidal inflammation 2 4.6
  Missing data 0 –
Comorbidities/Complications
  Glaucoma 6 14.0
  Ocular hypertension 2 4.6
  Epiretinal membrane 14 32.6
  Cataract 12 27.9
  Retinal ischaemia within the macula 8 18.6
  Retinal ischaemia within peripheral retina 12 27.9
*Missing data for one patient.
TNFi, tumour necrosis factor-alpha inhibitor; logMAR, logarithm of the minimum 
angle of resolution.
resulTs
study population
Of 85 patients within the registry, 43 met the inclusion criteria 
(table 1). Patients attended 1.5 (SD 0.4) clinic visits per year 
for a mean of 5.4 years (SD 2.2; range 1.2–11.3 years) to the 
census date (May 2015). Thirty-four (79%) patients were 
treated with a TNFi for over 2 years and 23 (54%) were treated 
for over 4 years. Thirty-eight completed at least two QoL 
questionnaires. Thirty-four patients commenced treatment 
with infliximab and nine with adalimumab. The median time 
on infliximab was 3.2 years (IQR 4.3) and on adalimumab was 
2.4 years (IQR 1.8).
The clinical indications for TNFi were grouped into three 
non-mutually exclusive categories: non-infectious uveitis or 
scleritis refractory to therapeutic doses of at least one immu-
nosuppressive therapy (n=30), patients who were intolerant of 
therapeutic doses of conventional immunosuppression (n=15), 
and patients who were experiencing rapid deterioration in vision 
(n=10). (For detailed baseline disease characteristics, see online 
supplementary table 1.
efficacy of anti-TnFα therapy: remission and relapse
Thirty-nine patients (91%) achieved sustained remission (0.5 
PPY) at a median time of 1.2 years from starting TNFi (figure 2) 
. Twenty-two (51%) of the cohort had a relapse (0.2 PPY) at 2.9 
years (median) (range 0.9–7.2 years) from commencing a TNFi 
(index). In five patients (12%) a second relapse occurred at 6.6 
years (range 2.9–9.2 years) from index. No patient had more 
than two relapses. Six out of nine (67%) patients who started 
on adalimumab achieved sustained remission; all six later expe-
rienced a relapse (median 2.0 years from index; IQR: 1.6). Thir-
ty-three of the 34 (97%) patients receiving infliximab achieved 
sustained remission. Relapse occurred in 18 patients (53%) 
(median 3.4 years from index; IQR: 2.7). Twenty-six patients 
received a steroid rescue treatment during follow-up (high-
dose oral prednisolone [n=21, intravenous methylpredniso-
lone n=11, intravitreal triamcinolone n=7], periocular steroid 
injection n=5). The rate of steroid rescue prior to commencing 
biologic therapy was 0.8 PPY for 33 of 43 patients in whom 
these data were available; the introduction of TNFi was associ-
ated with a reduction in steroid rescue (0.1 PPY; n=43) to census 
or cessation of the TNFi.
Visual acuity
At baseline, 32 (74%) patients met the driving licence standard 
for distance central visual acuity logMAR 0.3 (6/12 Snellen) 
(table 1). In 14 patients the visual acuity was better than or 
equal to logMAR 0 (6/6 Snellen). Two patients were legally 
blind in the better eye (logMAR 1, 6/60 Snellen). Overall, 79% 
subjects (n=34) maintained visual stability. This included 81% 
(n=32) of those with vision of logMAR 0.3 or better at base-
line and 86% (n=12) of those with baseline visual acuity of 
logMAR 0.
An improvement in vision (a gain in 15 ETDRS letters or 
more) occurred in three (7%) patients (0.01/PPY) at a mean of 
0.9 years from starting TNFi. The visual angle doubled (a loss of 
15 ETDRS letters or more) in nine patients (0.05 PPY) at a mean 
time of 1.8 years from index, although in one patient vision later 
recovered (online supplementary table 3).
New visual loss was attributed mainly to cataract (n=5), 
vitritis plus epiretinal membrane (n=2) and chronic cystoid 
macular oedema (n=2). In seven patients who lost vision during 
treatment, there was pre-existing visual loss due to structural 
complications, either due to retinal vasculitis involving the 
macula (n=5) or chronic cystoid macular oedema (n=2) (online 
supplementary table 3). Of those who lost vision, six patients 
had posterior or panuveitis, two had intermediate uveitis and 
one had anterior uveitis. Over 50% of the patients who lost 
vision on treatment had Behcet’s disease (n=5). Five out of nine 
were smokers or ex-smokers, three had never smoked, and in 
another the smoking status was unknown.
 o
n
 13 M
arch 2019 by guest. Protected by copyright.
http://bjo.bmj.com/
Br J O
phthalm
ol: first published as 10.1136/bjophthalmol-2018-312767 on 12 March 2019. Downloaded from 
4 Sharma SM, et al. Br J Ophthalmol 2019;0:1–7. doi:10.1136/bjophthalmol-2018-312767
Clinical science
Figure 2 Sustained remission and relapse during follow up. Kaplan Meier estimator curve of the probability ofpatients (y-axis) experiencing (A) 
sustained remission and (B) relapse following remission on eitheradalimumab or infliximab. The x-axis shows the time to either outcome.
Corticosteroid-sparing effect of TnFi
Prior to starting anti-TNFα therapy, 21 of 43 patients (49%) 
were on >10 mg prednisolone per day, 32 of 43 patients (74%) 
were on >7.5 mg per day Online supplementary table 2), and 
25 of 32 patients (78%) reduced to less than 7.5 mg at a rate of 
0.3 PPY by 1.9 years (IQR: 1.7). Thirty-nine per cent (n=15) 
of patients were able to withdraw steroids completely at a rate 
of 0.09 PPY by 2 years (IQR 1.7). (For changes in concomitant 
immunomodulatory therapies, see (online supplementary table 
2).
Adverse events
Twenty-three (54%) patients had at least one AE (0.35 PPY) 
(table 2). There were more side effects on infliximab (n=28) 
compared with adalimumab (n=15) but with a similar rate 
(0.38 PPY vs 0.34 PPY). These included hypersensitivity reac-
tions (n=9) and headache (n=8). One patient had an anaphy-
lactic response to infliximab, seven experienced an infection 
(six infliximab, one adalimumab), and one developed miliary 
TB on infliximab (see the Discussion section). One patient was 
diagnosed with non-Hodgkin’s lymphoma (see the Discussion 
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Table 2 Number of patients experiencing side effects during TNFi 
treatment
Adalimumab Infliximab Total
Infusion-related reaction
  Mild 0 (0) 6 (18) 6 (14)
  Severe 0 (0) 3 (9) 3 (7)
Anaphylaxis
  Anaphylaxis 0 (0) 1 (3) 1 (2)
Infection
  Respiratory 1 (11) 3 (9) 4 (9)
  Abscesses 0 (0) 1 (3) 1 (2)
  Miliary tuberculosis 0 (0) 1 (3) 1 (2)
  Cellulitis with septicaemia 0 (0) 1 (3) 1 (2)
Neoplasia
  Non-Hodgkin’s lymphoma 1 (11) 0 (0) 1 (2)
Cutaneous
  Injection site cutaneous 1 (11) 0 (0) 1 (2)
  Psoriasis 0 (0) 1 (3) 1 (2)
  Alopecia 1 (11) 0 (0) 1 (2)
  Other rash 0 (0) 4 (12) 4 (9)
Other
  Lupus 0 (0) 2 (6) 2 (5)
  Myalgia 2 (22) 0 (0) 2 (5)
  Fatigue 1 (11) 3 (9) 4 (9)
  Headache 2 (22) 0 (0) 2 (5)
  Arthralgia 2 (22) 1 (3) 3 (7)
  Back pain 0 (0) 1 (3) 1 (2)
  Nausea 2 (22) 0 (0) 2 (5)
  Haematuria 1 (11) 0 (0) 1 (2)
  Night sweats 1 (11) 0 (0) 1 (2)
  Gout 1 (11) 0 (0) 1 (2)
  Mood disturbance 1 (11) 0 (0) 1 (2)
Total 17 28 45
Percentage proportions are shown in brackets.
TNFi, tumour necrosis factor-alpha inhibitor.
Figure 3 General quality of life and visual quality of life Mean 
change in General QoL (SF36)* and Visual QoL* (VCM1) scores from 
the baseline visit to each year of treatment on either adalimumab or 
infliximab. (A) SF36 mental component, (B) SF36 physical component 
and (C) VCM1 Visual QoL. (N indicates the number of participants for 
each year of treatment. Error bars represent the standard error. For SF36, 
a positive change indicates improvement of QoL. For VCM, a negative 
change indicates improvement of visual QoL. *The SF36 summarises 8 
dimensions of general health into a Physical Component Score (PCS) 
and a Mental Component score (MCS), ranging from 0 to 100 (best 
score).12 The VCM1 is a 10 point visual QoL which captures patient–
reported measures of visual health on emotional, physical, social and 
psychological aspects of visual quality of life.8 13 14 23section). There were no cardiovascular events, demyelinating 
episodes and no deaths.
stopping TnFi and switching biologic therapies
Twenty-three per cent (10 patients) changed biologic agent (0.04 
PPY, median time from index of 1.7 years). Eight patients were 
switched from infliximab to adalimumab (0.04 PPY) for conve-
nience of administration (n=4, 0.02 PPY), primary lack of effi-
cacy (n=2, 0.01 PPY) or an AE related to infliximab use (n=2, 
0.01 PPY); all were followed by remission. No patients were 
switched from adalimumab to infliximab.
TNFi was changed to a different class of biologic therapy 
in two patients (infliximab to tocilizumab; one switched from 
adalimumab to interferonα-2α after failing two TNFi). Ten 
patients (26%) stopped treatment (0.05 PPY), including those 
who stopped due to poor efficacy (2 infliximab [0.02 PPY]) or 
AEs (0.02 PPY) (2 infliximab [0.04 PPY], 2 adalimumab [0.01 
PPY]).
Quality of life
There was a non-statistically significant improvement in the 
VCM1 score, SF-36 Physical Component Score (PCS) and SF-36 
Mental Component Score (MCS) summary scores following the 
start of TNFi by a median of 1.7, 10 and 16 points, respectively, 
in year 1 (figure 3). Visual acuity alone was independently 
predictive of a VCM1 score above 2.0. (p=4×10−5). The VCM1 
and SF-36 scores were maintained throughout treatment. Better 
visual acuity (p=2×10−8) and longer duration of treatment 
(p=0.03) contributed to general QoL scores.
dIsCussIon
In a real-world prospective analysis, we found that regular, 
scheduled dosing with TNFi was successful in inducing sustained 
remission in 91% of adult patients, and a sustained corticoste-
roid-sparing effect was observed in three-quarters of the patients. 
There were no new safety signals and QoL was maintained during 
treatment. At the census date, 77% had quiescent inflammation. 
In eight patients who had active inflammation at census, cystoid 
macular oedema (CMO) and vitritis were the main features. This 
is comparable with 65% of patients who were quiescent during 
the VISUAL III trial after 78 weeks’ follow-up.7
A key goal of treatment of ocular inflammation is maintenance 
of remission after achieving disease control. We observed that 
51% of patients experience at least one relapse of inflamma-
tion. An initial relapse occurring 2.7 years from commencing a 
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biologic was followed by a second nearly 4 years later in 12% of 
patients. Supporting the results of the VISUAL II trial, our data 
imply that a single relapse, adequately treated, may be followed 
by a long period of remission and does not predict treatment 
cessation.2
Sustained remission as an endpoint is a surrogate of long-term 
disease control. A previous report using a sustained remission 
endpoint demonstrated 60% of patients on TNFi achieved remis-
sion after 6 months of treatment.15 In our cohort, the median 
time to a sustained remission was 1.2 years. The difference may 
be due to overestimation of time to remission in our data due to 
missed study clinic appointments and the fact that six patients 
had started TNFi in excess of a year before the prospective arm 
of the study, where no retrospective data informed index to 
remission time.
Switching biologics is a means of restoring disease control. In 
a study of juvenile idiopathic arthritis, switching from infliximab 
to adalimumab resulted in disease remission in 75% of patients.16 
In Behcet’s disease, switching TNFi led to drug-induced remis-
sion of uveitis in 11 out of 13 patients.17 Here we show that for 
10 patients, changing TNFi does not negatively impact clinical 
outcomes. However, patient preference directed the switch in 4 
out of the 10 patients, and the sample size is too small to draw 
firm conclusions.
During treatment 79% (n=34) experienced stability or 
improvement of vision, while 19% (8 patients) lost vision. Over 
half of those with loss of vision also had a history of smoking, 
which has been linked to visual loss in retinal vasculitis.18 A 
multicentre study of adalimumab in chronic uveitis reported a 
gain in vision in 21% of patients and a loss of vision in 3.7% of 
patients over a 6-month period of follow-up. One may anticipate 
that the refractory, advanced nature of disease in this cohort and 
the presence of structural complications are highly likely to be 
factors in the failure to arrest further visual loss.
Adverse events
Twenty-three patients (54%; 0.35 PPY) experienced at least one 
side effect and SAEs occurring at a rate of 0.02 PPY. A similar 
rate of SAEs (0.02 PPY) but a higher overall AE rate (4.2 PPY) 
was noted in VISUAL III.7 In a French study of long-term 
outcomes with TNFi, 28% of patients experienced AEs and the 
frequency of neoplastic events (2.5%) was similar to ours (2%).19 
In a 2-year follow-up study of a prospective, open-label trial of 
infliximab, 3 out of 31 (10%) participants reported malignan-
cies, while 29% experienced AEs overall.20 A review of several 
study designs showed that discontinuation of TNFi due to AEs 
was 0.02 PPY for adalimumab and 0.06 PPY for infliximab.21
These AE data demonstrate continued need for vigilance. In 
our cohort, two patients required hospitalisation for infections 
and temporary cessation of therapy. A case of miliary TB despite 
previously negative tuberculin test (Purified Protein Derivative 
(PPD)) and normal chest X-ray highlights the risk of acquiring 
TB while on TNFi. There was one case of a non-fatal non-Hod-
gkin’s lymphoma in a patient presenting with a new abdominal 
mass 8 months after starting adalimumab for idiopathic panuve-
itis in whom a causal relationship with adalimumab is possible.
limitations
Study limitations include the use of retrospective baseline data 
for six patients. Although there may be disease-specific differ-
ences in response to TNFi, these differences are likely to be small 
in in such a heterogeneous cohort. Our data suggest that patients 
are more likely to achieve a sustained remission with infliximab 
but experience a similar rate of relapse to patients on adalim-
umab. A report of 164 patients showed no differential response 
to either TNFi agent19 and similar results were observed in 
children.22
ConClusIon
A contemporary approach to uveitis treatment includes biologic 
therapy. This prospective report supports long-term TNFi 
associated with no attrition of QoL despite the requirement 
for several years of treatment. Side effects were frequent, and 
although SAEs are infrequent they remain an appreciable risk. 
Patients may require inclass switching or change in biologic due 
to AEs or loss of efficacy. This emphasises that, despite successful 
TNFi, wider treatment options are necessary, as well as further 
assessment of which uveitic entities respond best, in order to 
optimise outcomes.
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